YouTube Facebook LinkedIn Google+ Twitter Xingrss  



Paper View 

Incyte Committed to Genomics 
Your recent article "Genomics Companies Must Fill the Pipeline or Face the Music"(June 2003 Bio·IT World, page 1) may have given your readers the inaccurate impression that because of Incyte's move into drug discovery we are no longer interested in genomics-based research. You also have implied that we do not value our intellectual property — nothing could be further from the truth.

Our move into drug discovery was a logical, strategic decision. It has enabled us to build on our leadership position in genomics and biological information, while creating an advantageous approach to the discovery and development of novel, proprietary medicines. Simultaneous with our efforts to build our drug discovery programs, we continue to refine our database product offerings to adapt to the evolving needs of the industry, making them more pharmaceutically relevant and user-friendly.

Incyte's intellectual property is a valuable asset, which currently generates significant revenues and has the potential to grow substantially. Our broad patent portfolio, covering important genomic technologies as well as numerous patents relating to genes and proteins, provides our database customers and our own drug discovery team with freedom to operate. We expect to realize additional value through collaborations involving therapeutic antibodies, from additional strategic licenses for our proprietary technologies, and from future product royalties.

In summary, we have not abandoned genomics for drug discovery or our commitment to leadership in this field. In fact, we fully expect to capitalize on our expertise in this area by effectively and efficiently using genomic information to develop important new medicines.

Paul A. Friedman, M.D.
Chief Executive Officer
Incyte



Contact Us

E-mail your comments to:
  editor@bio-itworld.com
Or address snail mail to:
  P.O. Box 9010
  500 Old Connecticut Path
  Framingham, MA 01701







For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.